NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea; 3D Convergence Center, Inha University, Incheon 22212, Republic of Korea.
Department of Bioscience and Biotechnology, Banasthali University, Vanasthali, Rajasthan 304022, India.
Biomed Pharmacother. 2023 Jul;163:114822. doi: 10.1016/j.biopha.2023.114822. Epub 2023 May 3.
Breast cancer (BC) is the second most fatal disease and is the prime cause of cancer allied female deaths. BC is caused by aberrant tumor suppressor genes and oncogenes regulated by transcription factors (TFs) like NF-κB. NF-κB is a pro-inflammatory TF that crucially alters the expressions of various genes associated with inflammation, cell progression, metastasis, and apoptosis and modulates a network of genes that underlie tumorigenesis. Herein, we focus on NF-κB signaling pathways, its regulators, and the rationale for targeting NF-κB. This review also includes TFs that maintain NF-κB crosstalk and their roles in promoting angiogenesis and metastasis. In addition, we discuss the importance of combination therapies, resistance to treatment, and potential novel therapeutic strategies including nanomedicine that targets NF-κB.
乳腺癌（BC）是第二大致命疾病，也是导致女性癌症相关死亡的主要原因。BC 是由异常的肿瘤抑制基因和癌基因引起的，这些基因受转录因子（TFs）如 NF-κB 的调节。NF-κB 是一种促炎 TF，它会显著改变与炎症、细胞进展、转移和凋亡相关的各种基因的表达，并调节肿瘤发生的基因网络。在此，我们重点介绍 NF-κB 信号通路、其调节剂以及针对 NF-κB 的合理策略。本综述还包括维持 NF-κB 串扰的 TFs 及其在促进血管生成和转移中的作用。此外，我们还讨论了联合治疗的重要性、治疗耐药性以及包括针对 NF-κB 的纳米医学在内的潜在新型治疗策略。
